Ownership and insider activity for Matinas BioPharma Holdings, Inc. (MTNB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts.
Price
| Price | $0.17 |
| Market Cap | $1M |
| Exchange | AMEX |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.1M | $7.3M | $12.4M | $22.2M | $12.4M | $21.0M | $6.9M | $4.8M | $7.3M | $4.0M |
| Short-term Investments | 0 | 0 | 0 | $5.6M | $46.2M | $28.6M | $21.9M | $9.0M | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $4.6M | $8.0M | $13.1M | $29.9M | $61.6M | $51.0M | $34.5M | $15.5M | $8.0M | $4.1M |
| Property, Plant & Equipment | $356000 | $1.6M | $2.0M | $5.6M | $4.9M | $5.8M | $5.7M | $5.0M | $2.2M | $673000 |
| Goodwill | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | 0 | 0 |
| Intangible Assets | $3.0M | $3.0M | $3.0M | $3.0M | $3.0M | $3.0M | $3.0M | $3.0M | $2.3M | $2.3M |
| Total Assets | $9.8M | $14.4M | $19.9M | $40.2M | $71.0M | $61.3M | $78.9M | $25.1M | $12.6M | $7.2M |
| Accounts Payable | $475602 | $582867 | $295652 | $679310 | $349941 | $937000 | $618000 | $514000 | $95000 | $315000 |
| Short-term Debt | $118046 | $170236 | $199842 | 0 | 0 | 0 | $569000 | 0 | 0 | $696000 |
| Total Current Liabilities | $1.4M | $2.2M | $2.8M | $3.1M | $3.6M | $4.3M | $4.3M | $2.6M | $2.7M | $1.5M |
| Long-term Debt | 0 | 0 | 0 | $3.75B | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $2.7M | $3.7M | $3.8M | $7.2M | $7.2M | $8.8M | $42.2M | $5.9M | $5.1M | $2.4M |
| Retained Earnings | -$35.2M | -$51.3M | -$65.9M | -$84.4M | -$107.5M | -$131.6M | -$152.6M | -$175.6M | -$199.8M | -$210.8M |
| Total Equity | $7.1M | $10.7M | $16.1M | $33.1M | $63.7M | $52.5M | $36.6M | $19.2M | $7.6M | $4.8M |
| Total Debt | $144428 | $264894 | $390743 | $4.2M | $3.8M | $4.7M | $4.1M | $3.6M | $2.9M | $1.4M |
| Net Debt | -$4.0M | -$7.0M | -$12.1M | -$23.5M | -$54.9M | -$44.9M | -$24.7M | -$10.2M | -$4.4M | -$2.6M |
| Working Capital | $3.1M | $5.7M | $10.2M | $26.8M | $58.0M | $46.6M | $30.2M | $12.9M | $5.4M | $2.6M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 0.85 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -42.88 |
Profitability
| Return on Equity | -181.45% |
| Return on Invested Capital | -323.22% |
| Return on Assets | -214.21% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · ADIL · ADXN · BCLI · CDIO · HCWB · IBO
Explore sector: Healthcare · Biotechnology
More sections of MTNB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks